Clinical Trials Logo

GEN1 Gene Mutation clinical trials

View clinical trials related to GEN1 Gene Mutation.

Filter by:
  • None
  • Page 1

NCT ID: NCT04975048 Completed - Healthy Clinical Trials

SREBF1 Polymorphism and Egg Yolk on Cardiovascular Disease Risk in Healthy Young Adults: a Randomised, Two-period, Single Blinded, Crossover Trial

Start date: July 1, 2019
Phase: N/A
Study type: Interventional

Our previous analysis showed that sterol regulatory element binding protein gene (SREBF1) rs2236513/rs2297508/rs4925119 polymorphism modulated the relation between dietary cholesterol and serum low density lipoprotein cholesterol /serum total cholesterol. This study aims to confirm and extend this finding by characterizing the effects of cholesterol from egg yolks on lipid profiles in healthy young adults with different SREBF1 genetic makeup. 32 SREBF1 C/G/G minor allele carriers at rs2236513/rs2297508/rs4925119 and 32 SREBF1 AA/CC/AA major homozygotes at rs2236513/rs2297508/rs4925119 were enrolled to test their response to egg yolks.

NCT ID: NCT04859543 Recruiting - Pediatric Cancer Clinical Trials

Pediatric Prospective Personalized Immune and Target Identification Trial

PPROSPERITIT
Start date: February 1, 2021
Phase: N/A
Study type: Interventional

PPROSPERITIT is a prospective clinical study assessing the use of comprehensive molecular profiling to define the best matching targeted and immune treatment for relapsed, refractory or very high risk pediatric CNS tumors.

NCT ID: NCT04030559 Recruiting - Prostate Carcinoma Clinical Trials

Niraparib Before Surgery in Treating Patients With High Risk Localized Prostate Cancer and DNA Damage Response Defects

Start date: February 25, 2020
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well niraparib, when given before surgery, works in treating patients with high risk prostate cancer that has not spread to other parts of the body (localized) and alterations in deoxyribonucleic acid (DNA) repair pathways. Niraparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.